Literature DB >> 33782838

Combination of cassette-dosing and microsampling for reduced animal usage for antibody pharmacokinetics in cynomolgus monkeys, wild-type mice, and human FcRn transgenic mice.

Miho Nagayasu1, Kazuhisa Ozeki2.   

Abstract

PURPOSE: The aim of this study was to develop a useful antibody PK evaluation tool using a combination of cassette-dosing and microsampling in mice and monkeys in order to reduce the number of animals used.
METHODS: Cetuximab, denosumab, infliximab, and a mixture of the three antibodies, i.e., cassette-dosing, were administered intravenously to cynomolgus monkeys, C57BL/6J mice, and homozygous human neonatal Fc-receptor transgenic (Tg32) mice. Mouse blood was collected from one animal continuously via the jugular vein at nine points.
RESULTS: In cynomolgus monkeys, infliximab showed faster elimination in the cassette-dosing group than in the single-dose group. Anti-drug antibody production was observed, but the PK parameters of the clearance and distribution volume were similar in both groups. In C57BL/6J and Tg32 mice, each of the plasma concentrations-time profiles after cassette-dosing were similar to those after single dosing. PK evaluation using a combination of cassette-dosing and microsampling in mice may reduce the number of mice used by approximately 90% compared with the conventional method.
CONCLUSIONS: The combination of antibody cassette-dosing and microsampling is a promising PK evaluation method as a high-throughput and reliable with reduced numbers of mice and cynomolgus monkeys.

Entities:  

Keywords:  antibody; cassette-dosing; cynomolgus monkey; human FcRn transgenic mice; microsampling

Year:  2021        PMID: 33782838     DOI: 10.1007/s11095-021-03028-6

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  27 in total

1.  Prediction of human plasma concentration-time profiles of monoclonal antibodies from monkey data by a species-invariant time method.

Authors:  Masataka Oitate; Shintaro Nakayama; Takashi Ito; Atsushi Kurihara; Noriko Okudaira; Takashi Izumi
Journal:  Drug Metab Pharmacokinet       Date:  2011-12-06       Impact factor: 3.614

2.  One mouse, one pharmacokinetic profile: quantitative whole blood serial sampling for biotherapeutics.

Authors:  Alison P Joyce; Mengmeng Wang; Rosemary Lawrence-Henderson; Cynthia Filliettaz; Sheldon S Leung; Xin Xu; Denise M O'Hara
Journal:  Pharm Res       Date:  2014-01-24       Impact factor: 4.200

3.  Prediction of human pharmacokinetics of therapeutic monoclonal antibodies from simple allometry of monkey data.

Authors:  Masataka Oitate; Noriko Masubuchi; Takashi Ito; Yoshiyuki Yabe; Tsuyoshi Karibe; Takanori Aoki; Nobuyuki Murayama; Atsushi Kurihara; Noriko Okudaira; Takashi Izumi
Journal:  Drug Metab Pharmacokinet       Date:  2011-05-24       Impact factor: 3.614

4.  Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies.

Authors:  Lindsay B Avery; Mengmeng Wang; Mania S Kavosi; Alison Joyce; Jeffrey C Kurz; Yao-Yun Fan; Martin E Dowty; Minlei Zhang; Yiqun Zhang; Aili Cheng; Fei Hua; Hannah M Jones; Hendrik Neubert; Robert J Polzer; Denise M O'Hara
Journal:  MAbs       Date:  2016-05-27       Impact factor: 5.857

5.  Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization.

Authors:  Tomoyuki Igawa; Shinya Ishii; Tatsuhiko Tachibana; Atsuhiko Maeda; Yoshinobu Higuchi; Shin Shimaoka; Chifumi Moriyama; Tomoyuki Watanabe; Ryoko Takubo; Yoshiaki Doi; Tetsuya Wakabayashi; Akira Hayasaka; Shoujiro Kadono; Takuya Miyazaki; Kenta Haraya; Yasuo Sekimori; Tetsuo Kojima; Yoshiaki Nabuchi; Yoshinori Aso; Yoshiki Kawabe; Kunihiro Hattori
Journal:  Nat Biotechnol       Date:  2010-10-17       Impact factor: 54.908

6.  Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody.

Authors:  Kenta Haraya; Tatsuhiko Tachibana; Masahiko Nanami; Masaki Ishigai
Journal:  Xenobiotica       Date:  2014-07-17       Impact factor: 1.908

7.  Predicting Method for the Human Plasma Concentration-Time Profile of a Monoclonal Antibody from the Half-life of Non-human Primates.

Authors:  Genki Nakamura; Kazuhisa Ozeki; Miho Nagayasu; Takeru Nambu; Takayuki Nemoto; Ken-Ichi Hosoya
Journal:  Biol Pharm Bull       Date:  2020       Impact factor: 2.233

8.  An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.

Authors:  Michelle Kinder; Allison R Greenplate; William R Strohl; Robert E Jordan; Randall J Brezski
Journal:  MAbs       Date:  2015       Impact factor: 5.857

9.  Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life.

Authors:  Brian C Mackness; Julie A Jaworski; Ekaterina Boudanova; Anna Park; Delphine Valente; Christine Mauriac; Olivier Pasquier; Thorsten Schmidt; Mostafa Kabiri; Abdullah Kandira; Katarina Radošević; Huawei Qiu
Journal:  MAbs       Date:  2019-07-18       Impact factor: 5.857

10.  Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibody.

Authors:  Zenjiro Sampei; Kenta Haraya; Tatsuhiko Tachibana; Taku Fukuzawa; Meiri Shida-Kawazoe; Siok Wan Gan; Yuichiro Shimizu; Yoshinao Ruike; Shu Feng; Taichi Kuramochi; Masaru Muraoka; Takehisa Kitazawa; Yoshiki Kawabe; Tomoyuki Igawa; Kunihiro Hattori; Junichi Nezu
Journal:  PLoS One       Date:  2018-12-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.